Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (600613 SHG) stock market data APIs

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sales of pharmaceuticals in China and internationally. The company offers patented anti-tumor drugs; topical antibacterial series; products for hypertension, hyperlipidemia, and hyperglycemia chronic diseases; classic Chinese medicine cough relief series; classic tonic product series; Miao medicine for strengthening muscles and bones series; and magical doll medicine series. It also provides toothache relief drops; parsnicillin tablets, compound amino acid vitamin capsules, compound chlorhexidine dexamethasone, nasal and mouth cleansing spray, constipation relief capsules, anwei tablets, motherwort paste, gynecological menstrual regulating tablets, Sangju cold tablets, hawthorn granules, isatis root granules, col and cough syrup, and gastritis relief granules, as well as acetaminophen, caffeine, and flavoxate tablets. The companys products are used for therapeutic areas such as anti-tumor, cold and cough relief, cardiovascular and cerebrovascular diseases, rheumatic bone pain, antifungal, tonifying and calming mind, and gynecological diseases. In addition, it is involved in wholesale and retail trade, and culture and art businesses; provision of software and information technology services. It also exports its products. The company was founded in 1992 and is based in Shanghai, China.